Is Thyrocare Tech. overvalued or undervalued?

As of 23 June 2025, the valuation grade for Thyrocare Technologies has moved from very expensive to expensive. The company is currently considered overvalued. Key ratios include a PE ratio of 57.21, an EV to EBITDA of 26.67, and a PEG ratio of 1.95, which indicate high valuation relative to earnings and growth potential.
In comparison to peers, Max Healthcare has a significantly higher PE ratio of 102.18, while Apollo Hospitals is valued more attractively at a PE of 69.61. Despite Thyrocare's strong ROCE of 35.59% and ROE of 16.76%, its elevated valuation metrics suggest that it may not provide sufficient upside relative to its current price of 989.45. Over the past year, Thyrocare has outperformed the Sensex with a return of 55.42% compared to the Sensex's 6.07%, but the current valuation raises concerns about future growth sustainability.